Metabolic consequences of oncogenic IDH mutations

Pharmacology and Therapeutics

Volumn 152, Issue , 2015, Pages 54-62

  Parker, Seth J ^a   Metallo, Christian M ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Glucose oxidation; Metabolism; Mutant IDH inhibitors; Mutant IDH1 and IDH2; NADPH; Reductive carboxylation

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TRICARBOXYLIC ACID; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ALLELE; ARTICLE; CARBOXYLATION; CELL FUNCTION; CELL METABOLISM; ENZYME ACTIVITY; EPIGENETICS; GENE MUTATION; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HUMAN; ONCOGENE; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; ANIMAL; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); ENERGY METABOLISM; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROCEDURES;

ANIMALS; CARCINOGENESIS; CLINICAL TRIALS AS TOPIC; ENERGY METABOLISM; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 84933676801     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.05.003     Document Type: Review

References (128)

1. M.F. Amary, K. Bacsi, F. Maggiani, S. Damato, D. Halai, and F. Berisha IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours J Pathol 224 3 2011 334 343
2. G.K. Balendiran, R. Dabur, and D. Fraser The role of glutathione in cancer Cell Biochem Funct 22 6 2004 343 352
3. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 6 2008 597 602
4. D.C. Berwick, I. Hers, K.J. Heesom, S.K. Moule, and J.M. Tavare The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes J Biol Chem 277 37 2002 33895 33900
5. P. Birner, S. Pusch, C. Christov, S. Mihaylova, K. Toumangelova-Uzeir, and S. Natchev Mutant IDH1 inhibits PI3K/Akt signaling in human glioma Cancer 120 16 2014 2440 2447
6. A.M. Bleau, D. Hambardzumyan, T. Ozawa, E.I. Fomchenko, J.T. Huse, and C.W. Brennan PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells Cell Stem Cell 4 3 2009 226 235
7. F.E. Bleeker, N.A. Atai, S. Lamba, A. Jonker, D. Rijkeboer, and K.S. Bosch The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma Acta Neuropathol 119 4 2010 487 494
8. A. Bordbar, J.M. Monk, Z.A. King, and B.O. Palsson Constraint-based models predict metabolic and associated cellular functions Nat Rev Genet 15 2 2014 107 120
9. D.R. Borger, K.K. Tanabe, K.C. Fan, H.U. Lopez, V.R. Fantin, and K.S. Straley Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping Oncologist 17 1 2012 72 79
10. L.B. Bralten, N.K. Kloosterhof, R. Balvers, A. Sacchetti, L. Lapre, and M. Lamfers IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo Ann Neurol 69 3 2011 455 463
11. R.A. Cairns, I.S. Harris, and T.W. Mak Regulation of cancer cell metabolism Nat Rev Cancer 11 2 2011 85 95
12. R.A. Cairns, and T.W. Mak Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities Cancer Discov 3 7 2013 730 741
13. C. Ceccarelli, N.B. Grodsky, N. Ariyaratne, R.F. Colman, and B.J. Bahnson Crystal structure of porcine mitochondrial NADP+-dependent isocitrate dehydrogenase complexed with Mn2+ and isocitrate. Insights into the enzyme mechanism J Biol Chem 277 45 2002 43454 43462
14. S.M. Chan, D. Thomas, M.R. Corces-Zimmerman, S. Xavy, S. Rastogi, and W.J. Hong Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia Nat Med 21 2 2015 178 184
15. M.M. Chaumeil, P.E. Larson, S.M. Woods, L. Cai, P. Eriksson, and A.E. Robinson Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma Cancer Res 74 16 2014 4247 4257
16. R. Chen, M.C. Nishimura, S. Kharbanda, F. Peale, Y. Deng, and A. Daemen Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma Proc Natl Acad Sci U S A 111 39 2014 14217 14222
17. T. Cheng, J. Sudderth, C. Yang, A.R. Mullen, E.S. Jin, and J.M. Mates Pyruvate carboxylase is required for glutamine-independent growth of tumor cells Proc Natl Acad Sci U S A 108 21 2011 8674 8679
18. C. Chesnelong, M.M. Chaumeil, M.D. Blough, M. Al-Najjar, O.D. Stechishin, and J.A. Chan Lactate dehydrogenase A silencing in IDH mutant gliomas Neuro Oncol 16 5 2014 686 695
19. W.C. Chou, W.C. Lei, B.S. Ko, H.A. Hou, C.Y. Chen, and J.L. Tang The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia Leukemia 25 2 2011 246 253
20. R. Chowdhury, K.K. Yeoh, Y.M. Tian, L. Hillringhaus, E.A. Bagg, and N.R. Rose The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases EMBO Rep 12 5 2011 463 469
21. C.G. da Silva, C.A. Ribeiro, G. Leipnitz, C.S. Dutra-Filho, A.A. Wyse, and C.M. Wannmacher Inhibition of cytochrome c oxidase activity in rat cerebral cortex and human skeletal muscle by D-2-hydroxyglutaric acid in vitro Biochim Biophys Acta 1586 1 2002 81 91
22. C.V. Dang Role of aerobic glycolysis in genetically engineered mouse models of cancer BMC Biol 11 2013 3
23. C.V. Dang, J.W. Kim, P. Gao, and J. Yustein The interplay between MYC and HIF in cancer Nat Rev Cancer 8 1 2008 51 56
24. L. Dang, D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, and E.M. Driggers Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 7274 2009 739 744
25. R.J. DeBerardinis, J.J. Lum, G. Hatzivassiliou, and C.B. Thompson The biology of cancer: metabolic reprogramming fuels cell growth and proliferation Cell Metab 7 1 2008 11 20
26. R.J. DeBerardinis, and C.B. Thompson Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148 6 2012 1132 1144
27. H.J. Dubbink, W. Taal, R. van Marion, J.M. Kros, I. van Heuvel, and J.E. Bromberg IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 21 2009 1792 1795
28. R.L. Elstrom, D.E. Bauer, M. Buzzai, R. Karnauskas, M.H. Harris, and D.R. Plas Akt stimulates aerobic glycolysis in cancer cells Cancer Res 64 11 2004 3892 3899
29. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 8 2009 550 562
30. M. Esmaeili, B.C. Hamans, A.C. Navis, R. van Horssen, T.F. Bathen, and I.S. Gribbestad IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma Cancer Res 74 17 2014 4898 4907
31. J. Fan, J.J. Kamphorst, R. Mathew, M.K. Chung, E. White, and T. Shlomi Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia Mol Syst Biol 9 2013 712
32. J. Fan, J. Ye, J.J. Kamphorst, T. Shlomi, C.B. Thompson, and J.D. Rabinowitz Quantitative flux analysis reveals folate-dependent NADPH production Nature 510 7504 2014 298 302
33. S.M. Fendt, E.L. Bell, M.A. Keibler, S.M. Davidson, G.J. Wirth, and B. Fiske Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism Cancer Res 73 14 2013 4429 4438
34. M.E. Figueroa, O. Abdel-Wahab, C. Lu, P.S. Ward, J. Patel, and A. Shih Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 6 2010 553 567
35. T. Finkel, and N.J. Holbrook Oxidants, oxidative stress and the biology of ageing Nature 408 6809 2000 239 247
36. D. Gaglio, C.M. Metallo, P.A. Gameiro, K. Hiller, L.S. Danna, and C. Balestrieri Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth Mol Syst Biol 7 2011 523
37. P.A. Gameiro, J. Yang, A.M. Metelo, R. Perez-Carro, R. Baker, and Z. Wang In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation Cell Metab 17 3 2013 372 385
38. A.R. Grassian, S.J. Parker, S.M. Davidson, A.S. Divakaruni, C.R. Green, and X. Zhang IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism Cancer Res 74 12 2014 3317 3331
39. D. Guo, F. Reinitz, M. Youssef, C. Hong, D. Nathanson, and D. Akhavan An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway Cancer Discov 1 5 2011 442 456
40. C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, R. Guillevin, and J. Laffaire IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 17 2010 1560 1566
41. K. Ichimura Molecular pathogenesis of IDH mutations in gliomas Brain Tumor Pathol 29 3 2012 131 139
42. J.L. Izquierdo-Garcia, L.M. Cai, M.M. Chaumeil, P. Eriksson, A.E. Robinson, and R.O. Pieper Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase PLoS One 9 9 2014 e108289
43. G. Jin, Z.J. Reitman, C.G. Duncan, I. Spasojevic, D.M. Gooden, and B.A. Rasheed Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas Cancer Res 73 2 2013 496 501
44. G. Jin, Z.J. Reitman, I. Spasojevic, I. Batinic-Haberle, J. Yang, and O. Schmidt-Kittler 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations PLoS One 6 2 2011 e16812
45. T.A. Juratli, M. Peitzsch, K. Geiger, G. Schackert, G. Eisenhofer, and D. Krex Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas Neuro Oncol 15 6 2013 682 690
46. W.G. Kaelin Jr., and S.L. McKnight Influence of metabolism on epigenetics and disease Cell 153 1 2013 56 69
47. J.W. Kim, P. Gao, Y.C. Liu, G.L. Semenza, and C.V. Dang Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1 Mol Cell Biol 27 21 2007 7381 7393
48. J.W. Kim, I. Tchernyshyov, G.L. Semenza, and C.V. Dang HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia Cell Metab 3 3 2006 177 185
49. H. Kim, S.J. Won, C. Fabian, M. Kang, M. Szardenings, and M. Shin Mitochondrial DNA aberrations and pathophysiological implications in hematopoietic diseases, chronic inflammatory diseases, and cancers Ann Lab Med 35 1 2015 1 14
50. A. King, M.A. Selak, and E. Gottlieb Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer Oncogene 25 34 2006 4675 4682
51. P. Koivunen, S. Lee, C.G. Duncan, G. Lopez, G. Lu, and S. Ramkissoon Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation Nature 483 7390 2012 484 488
52. D. Koul PTEN signaling pathways in glioblastoma Cancer Biol Ther 7 9 2008 1321 1325
53. M. Kranendijk, E.A. Struys, E. van Schaftingen, K.M. Gibson, W.A. Kanhai, and M.S. van der Knaap IDH2 mutations in patients with D-2-hydroxyglutaric aciduria Science 330 6002 2010 336
54. M. Labussiere, A. Idbaih, X.W. Wang, Y. Marie, B. Boisselier, and C. Falet All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 23 2010 1886 1890
55. A. Lai, S. Kharbanda, W.B. Pope, A. Tran, O.E. Solis, and F. Peale Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin J Clin Oncol 29 34 2011 4482 4490
56. A. Latini, C.G. da Silva, G.C. Ferreira, P.F. Schuck, K. Scussiato, and J.J. Sarkis Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues Mol Genet Metab 86 1-2 2005 188 199
57. A. Le, A.N. Lane, M. Hamaker, S. Bose, A. Gouw, and J. Barbi Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells Cell Metab 15 1 2012 110 121
58. R. Leonardi, C. Subramanian, S. Jackowski, and C.O. Rock Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation J Biol Chem 287 18 2012 14615 14620
59. C.A. Lewis, S.J. Parker, B.P. Fiske, D. McCloskey, D.Y. Gui, and C.R. Green Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells Mol Cell 55 2 2014 253 263
60. S. Li, A.P. Chou, W. Chen, R. Chen, Y. Deng, and H.S. Phillips Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation Neuro Oncol 15 1 2013 57 68
61. J.A. Losman, and W.G. Kaelin Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer Genes Dev 27 8 2013 836 852
62. J.A. Losman, R.E. Looper, P. Koivunen, S. Lee, R.K. Schneider, and C. McMahon (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible Science 339 6127 2013 1621 1625
63. C. Lu, S. Venneti, A. Akalin, F. Fang, P.S. Ward, and R.G. Dematteo Induction of sarcomas by mutant IDH2 Genes Dev 27 18 2013 1986 1998
64. C. Lu, P.S. Ward, G.S. Kapoor, D. Rohle, S. Turcan, and O. Abdel-Wahab IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 483 7390 2012 474 478
65. S.Y. Lunt, and M.G. Vander Heiden Aerobic glycolysis: meeting the metabolic requirements of cell proliferation Annu Rev Cell Dev Biol 27 2011 441 464
66. E.D. MacKenzie, M.A. Selak, D.A. Tennant, L.J. Payne, S. Crosby, and C.M. Frederiksen Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells Mol Cell Biol 27 9 2007 3282 3289
67. P.C. Mahon, K. Hirota, and G.L. Semenza FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev 15 20 2001 2675 2686
68. E.R. Mardis, L. Ding, D.J. Dooling, D.E. Larson, M.D. McLellan, and K. Chen Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 361 11 2009 1058 1066
69. I. Marin-Valencia, C. Yang, T. Mashimo, S. Cho, H. Baek, and X.L. Yang Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo Cell Metab 15 6 2012 827 837
70. C.M. Metallo, P.A. Gameiro, E.L. Bell, K.R. Mattaini, J. Yang, and K. Hiller Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia Nature 481 7381 2012 380 384
71. C.M. Metallo, and M.G. Vander Heiden Understanding metabolic regulation and its influence on cell physiology Mol Cell 49 3 2013 388 398
72. R.J. Molenaar, T. Radivoyevitch, J.P. Maciejewski, C.J. van Noorden, and F.E. Bleeker The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation Biochim Biophys Acta 1846 2 2014 326 341
73. I. Moroni, M. Bugiani, L. D'Incerti, C. Maccagnano, M. Rimoldi, and L. Bissola l-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology 62 10 2004 1882 1884
74. A.R. Mullen, and R.J. DeBerardinis Genetically-defined metabolic reprogramming in cancer Trends Endocrinol Metab 23 11 2012 552 559
75. A.R. Mullen, W.W. Wheaton, E.S. Jin, P.H. Chen, L.B. Sullivan, and T. Cheng Reductive carboxylation supports growth in tumour cells with defective mitochondria Nature 481 7381 2012 385 388
76. D.A. Mustafa, S.M. Swagemakers, L. Buise, P.J. van der Spek, and J.M. Kros Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities? Acta Neuropathol Commun 2 2014 6
77. I. Papandreou, R.A. Cairns, L. Fontana, A.L. Lim, and N.C. Denko HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption Cell Metab 3 3 2006 187 197
78. D.W. Parsons, S. Jones, X. Zhang, J.C. Lin, R.J. Leary, and P. Angenendt An integrated genomic analysis of human glioblastoma multiforme Science 321 5897 2008 1807 1812
79. N. Pollak, C. Dolle, and M. Ziegler The power to reduce: pyridine nucleotides - small molecules with a multitude of functions Biochem J 402 2 2007 205 218
80. J. Popovici-Muller, J.O. Saunders, F.G. Salituro, J.M. Travins, S. Yan, and F. Zhao Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo ACS Med Chem Lett 3 10 2012 850 855
81. T. Porstmann, C.R. Santos, B. Griffiths, M. Cully, M. Wu, and S. Leevers SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth Cell Metab 8 3 2008 224 236
82. S. Pusch, L. Schweizer, A.C. Beck, J.M. Lehmler, S. Weissert, and J. Balss d-2-hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma Acta Neuropathol Commun 2 2014 19
83. M.J. Rardin, S.E. Wiley, R.K. Naviaux, A.N. Murphy, and J.E. Dixon Monitoring phosphorylation of the pyruvate dehydrogenase complex Anal Biochem 389 2 2009 157 164
84. Z.J. Reitman, C.G. Duncan, E. Poteet, A. Winters, L.J. Yan, and D.M. Gooden Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia J Biol Chem 289 34 2014 23318 23328
85. Z.J. Reitman, G. Jin, E.D. Karoly, I. Spasojevic, J. Yang, and K.W. Kinzler Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome Proc Natl Acad Sci U S A 108 8 2011 3270 3275
86. A.R. Rendina, B. Pietrak, A. Smallwood, H. Zhao, H. Qi, and C. Quinn Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism Biochemistry 52 26 2013 4563 4577
87. D. Rohle, J. Popovici-Muller, N. Palaskas, S. Turcan, C. Grommes, and C. Campos An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 340 6132 2013 626 630
88. N.R. Rose, M.A. McDonough, O.N. King, A. Kawamura, and C.J. Schofield Inhibition of 2-oxoglutarate dependent oxygenases Chem Soc Rev 40 8 2011 4364 4397
89. P. Ru, T.M. Williams, A. Chakravarti, and D. Guo Tumor metabolism of malignant gliomas Cancers (Basel) 5 4 2013 1469 1484
90. R. Rzem, M.F. Vincent, E. Van Schaftingen, and M. Veiga-da-Cunha l-2-hydroxyglutaric aciduria, a defect of metabolite repair J Inherit Metab Dis 30 5 2007 681 689
91. S.S. Sabharwal, and P.T. Schumacker Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat Rev Cancer 14 11 2014 709 721
92. M. Sasaki, C.B. Knobbe, M. Itsumi, A.J. Elia, I.S. Harris, and I.I. Chio d-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function Genes Dev 26 18 2012 2038 2049
93. M. Sasaki, C.B. Knobbe, J.C. Munger, E.F. Lind, D. Brenner, and A. Brustle IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics Nature 488 7413 2012 656 659
94. D.A. Scott, A.D. Richardson, F.V. Filipp, C.A. Knutzen, G.G. Chiang, and Z.A. Ronai Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect J Biol Chem 286 49 2011 42626 42634
95. M.A. Selak, S.M. Armour, E.D. MacKenzie, H. Boulahbel, D.G. Watson, and K.D. Mansfield Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase Cancer Cell 7 1 2005 77 85
96. M.J. Seltzer, B.D. Bennett, A.D. Joshi, P. Gao, A.G. Thomas, and D.V. Ferraris Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1 Cancer Res 70 22 2010 8981 8987
97. G.L. Semenza, P.H. Roth, H.M. Fang, and G.L. Wang Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1 J Biol Chem 269 38 1994 23757 23763
98. I. Shechter, P. Dai, L. Huo, and G. Guan IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells J Lipid Res 44 11 2003 2169 2180
99. J. Shi, B. Sun, W. Shi, H. Zuo, D. Cui, and L. Ni Decreasing GSH and Increasing ROS in Chemosensitivity Gliomas with IDH1 Mutation 2014 Tumour Biol
100. T. Sjoblom, S. Jones, L.D. Wood, D.W. Parsons, J. Lin, and T.D. Barber The consensus coding sequences of human breast and colorectal cancers Science 314 5797 2006 268 274
101. J. Son, C.A. Lyssiotis, H. Ying, X. Wang, S. Hua, and M. Ligorio Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway Nature 496 7443 2013 101 105
102. Q. SongTao, Y. Lei, G. Si, D. YanQing, H. HuiXia, and Z. XueLin IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma Cancer Sci 103 2 2012 269 273
103. E.A. Struys D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect J Inherit Metab Dis 29 1 2006 21 29
104. H. Tarhonskaya, A.M. Rydzik, I.K. Leung, N.D. Loik, M.C. Chan, and A. Kawamura Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases Nat Commun 5 2014 3423
105. D.A. Tennant, R.V. Duran, and E. Gottlieb Targeting metabolic transformation for cancer therapy Nat Rev Cancer 10 4 2010 267 277
106. A.S. Tibbetts, and D.R. Appling Compartmentalization of Mammalian folate-mediated one-carbon metabolism Annu Rev Nutr 30 2010 57 81
107. M. Tonjes, S. Barbus, Y.J. Park, W. Wang, M. Schlotter, and A.M. Lindroth BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1 Nat Med 19 7 2013 901 908
108. S. Turcan, D. Rohle, A. Goenka, L.A. Walsh, F. Fang, and E. Yilmaz IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 7390 2012 479 483
109. E. Van Schaftingen, R. Rzem, A. Marbaix, F. Collard, M. Veiga-da-Cunha, and C.L. Linster Metabolite proofreading, a neglected aspect of intermediary metabolism J Inherit Metab Dis 36 3 2013 427 434
110. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 5930 2009 1029 1033
111. M. Wajne, C.R. Vargas, C. Funayama, A. Fernandez, M.L. Elias, and S.I. Goodman d-2-hydroxyglutaric aciduria in a patient with a severe clinical phenotype and unusual MRI findings J Inherit Metab Dis 25 1 2002 28 34
112. H. Wakimoto, S. Tanaka, W.T. Curry, F. Loebel, D. Zhao, and K. Tateishi Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas Clin Cancer Res 20 11 2014 2898 2909
113. F. Wang, J. Travins, B. DeLaBarre, V. Penard-Lacronique, S. Schalm, and E. Hansen Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation Science 340 6132 2013 622 626
114. O. Warburg On respiratory impairment in cancer cells Science 124 3215 1956 269 270
115. P.S. Ward, J.R. Cross, C. Lu, O. Weigert, O. Abel-Wahab, and R.L. Levine Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production Oncogene 31 19 2012 2491 2498
116. P.S. Ward, C. Lu, J.R. Cross, O. Abdel-Wahab, R.L. Levine, and G.K. Schwartz The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization J Biol Chem 288 6 2013 3804 3815
117. P.S. Ward, J. Patel, D.R. Wise, O. Abdel-Wahab, B.D. Bennett, and H.A. Coller The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 3 2010 225 234
118. T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 4 2009 1149 1153
119. S.C. Williams, M.A. Karajannis, L. Chiriboga, J.G. Golfinos, A. von Deimling, and D. Zagzag R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma Acta Neuropathol 121 2 2011 279 281
120. D.R. Wise, P.S. Ward, J.E. Shay, J.R. Cross, J.J. Gruber, and U.M. Sachdeva Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability Proc Natl Acad Sci U S A 108 49 2011 19611 19616
121. M. Xiao, H. Yang, W. Xu, S. Ma, H. Lin, and H. Zhu Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors Genes Dev 26 12 2012 1326 1338
122. W. Xu, H. Yang, Y. Liu, Y. Yang, P. Wang, and S.H. Kim Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases Cancer Cell 19 1 2011 17 30
123. X. Xu, J. Zhao, Z. Xu, B. Peng, Q. Huang, and E. Arnold Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity J Biol Chem 279 32 2004 33946 33957
124. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, and W. Yuan IDH1 and IDH2 mutations in gliomas N Engl J Med 360 8 2009 765 773
125. K. Yen, F. Wang, J. Travins, Y. Chen, Y. Hua, and K. Straley AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model Blood 122 21 2013
126. K. Yizhak, T. Benyamini, W. Liebermeister, E. Ruppin, and T. Shlomi Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model Bioinformatics 26 12 2010 i255 i260
127. S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, and P. Wang Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha Science 324 5924 2009 261 265
128. B. Zheng, Y. Yao, Z. Liu, L. Deng, J.L. Anglin, and H. Jiang Crystallographic investigation and selective inhibition of mutant isocitrate dehydrogenase ACS Med Chem Lett 4 6 2013 542 546